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Non-alcoholic fatty liver disease (NAFLD) is one of the most 
common liver diseases. NAFLD can further progress to irrevers-
ible liver failure such as non-alcoholic steatohepatitis (NASH) 
fibrosis and cirrhosis. However, specific regulator of NASH- 
fibrosis has yet to be established. Here, we found that gluta-
thione peroxidase 7 (GPx7) was markedly expressed in NASH 
fibrosis. Although GPx7 is an antioxidant enzyme protecting 
other organs, whether GPx7 plays a role in NASH fibrosis has 
yet to be studied. We found that knockdown of GPx7 in 
transforming growth factor- (TGF-) and free fatty acids (FFA)- 
treated LX-2 cells elevated the expression of pro-fibrotic and 
pro-inflammatory genes and collagen synthesis. Consistently, 
GPx7 overexpression in LX-2 cells led to the suppression of 
ROS production and reduced the expression of pro-fibrotic 
and pro-inflammatory genes. Further, NASH fibrosis induced 
by choline-deficient amino acid defined, high fat diet (CDAHFD) 
feeding was significantly accelerated by knockdown of GPx7, 
as evidenced by up-regulated liver fibrosis and inflammation 
compared with CDAHFD control mice. Collectively, these 
results suggest that GPx7 might be a novel therapeutic target to 
prevent the progression and development of NAFLD. [BMB 
Reports 2020; 53(6): 317-322]
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most 
common liver dysfunctions (1). NAFLD encompasses a spectrum 
of liver diseases, ranging from simple steatosis to steatosis 
combined with varying degrees of inflammation and fibrosis 
(2). The early stage of NAFLD involves simple steatosis, and is 
defined by a liver triglyceride content higher than 95% or by 
the triglyceride ratio in the cytoplasm 5% that of the liver (3, 
4). It is reversible via lifestyle intervention, such as exercise (5) 
or caloric restriction (6). Hepatic steatosis can progress to 
non-alcoholic steatohepatitis (NASH) fibrosis, which can lead 
to end-stage liver disease (2, 3). NASH fibrosis is accompanied 
by ballooning degeneration, cell death, inflammation and 
deposition of fibrous tissue (7, 8). More than 20% of all patients 
with NASH fibrosis progress to cirrhosis, an irreversible dis-
ease (9, 10). Thus, the survival rate of chronic liver disease 
depends substantially on the successful treatment of NASH 
fibrosis. However, no effective pharmacological treatments are 
currently available for NASH fibrosis.
Simple steatosis triggered by continuous fat accumulation in 
the liver induces oxidation and production of pro-inflam-
matory cytokines and adipokines (adiponectin, leptin, tumor 
necrosis factor alphas (TNF), and interleukin 6 (IL-6)) (3). 
However, the mechanism of NASH fibrosis progression is 
largely unknown. Hepatic stellate cells (HSCs) are one of the 
common triggers of NASH fibrosis development. Activation of 
HSCs by various stimuli (e.g., transforming growth factor beta 
(TGF-)) (11) that are transdifferentiated into myofibroblast-like 
cells strongly induces the secretion of fibrogenic mediators 
leading to excessive production of ECM proteins including 
collagen and alpha-smooth muscle actin (SMA) and release 
of inflammatory cytokines (12). Currently, many studies have 
shown that reactive oxygen species (ROS) might play a vital 
role in HSCs activation and proliferation (13). ROS production 
leads to NASH fibrosis via activation of HSCs (14, 15). 
GPx7 is a member of the glutathione peroxidase family 
(GPx1-8), which is a major family of antioxidant enzymes that 
effectively control the cellular contents of hydrogen peroxi-
dase (H2O2) and organic hydroperoxide by reduced gluta-
thione. Its main biological role is to protect the organism from 
oxidative damage (16). A recent study suggested that GPx7 is 
an oxidative stress sensor that transfers the ROS signals to its 
interacting proteins by shuttling disulfide bonds in response to 
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Fig. 1. GPx7 is highly expressed in NASH fibrosis. (A) Selected genes 
from RNA-seq. (B) Relative mRNA expression of GPx family in 
indicated mice liver. CD, chow diet; HFD, high-fat diet; CDAHFD, 
choline-deficient, amino-acid, high-fat diet. (C) Real-time PCR of 
GPx7 expression in simple steatosis and NASH fibrosis. All data 
are presented ± S.D. *P ＜ 0.05, **P ＜ 0.01, ***P ＜ 0.001.
Fig. 2. GPx7 prevents NASH fibrosis by suppressing ROS 
production. (A, B) Relative mRNA expression of indicated genes 
in LX-2 cells. Cells transfected with either negative control siRNA 
or si-GPx7 were treated with TOP. TOP, TGF- (3 ng) and FFA 
(1 mM OA, PA). (C) Sirus Red staining of LX-2 cells. Collagen, red; 
muscle fiber, yellow. (D) Cells transfected with the pcDNA3.0 or 
pcDNA3-GPx7-FLAG vector. Western blotting analysis using 
indicated antibodies. GAPDH was used as the loading control. (E) 
ROS production using flow cytometry of GPx7 overexpressed LX-2 
cells. All data are presented ± S.D. *P ＜ 0.05, ** P＜ 0.01, 
***P ＜ 0.001.
various stress (17). Peng et al. have reported that GPx7 
protects esophageal cells from bile acid-induced ROS pro-
duction (18, 19) and oxidative DNA damage modulates the 
critical upstream regulator of inflammatory NF-B signaling 
(20). However, the effects of GPx7 on NASH fibrosis remain 
unexplored. 
Thus, in the present study, we investigated whether GPx7 
expression is associated with the development of NASH fibro-
sis using in vitro and in vivo models. Here, we found that 
GPx7 was significantly upregulated in NASH fibrosis compared 
with normal and simple models of steatosis. Moreover, GPx7 
overexpression ameliorated NASH fibrosis via reduction of 
cellular ROS synthesis and regulation of pro-fibrotic and pro- 
inflammatory genes. In addition, GPx7 has been implicated in 
CDAHFD feeding-induced NASH fibrosis in vivo. Taken together, 
our findings indicate that GPx7 represents a promising target 
for the development of effective prophylactic and therapeutic 
strategy against NASH fibrosis.
RESULTS
GPx7 is highly expressed in non-alcoholic steatohepatitis
To identify the specific regulator of NASH fibrosis, we 
conducted RNA sequencing using in vitro and in vivo models 
of simple steatosis and NASH fibrosis. Simple models of 
steatosis were the oleic acid (OA)-treated Hepa1-6 cells and 
high fat diet (HFD)-fed mice. NASH fibrosis was induced by 
TGF- and FFA in LX-2 cells and CDAHFD in mice. In 
RNA-seq, we obtained several genes, which were expressed 
more than two-fold higher in NASH fibrosis than in simple 
steatosis (Fig. 1A). Among these genes, only GPx7 expression 
was highly increased in NASH fibrosis-specific manner. The 
expression level of each GPx isoform in simple steatosis and 
NASH fibrosis was confirmed using RT-PCR (Fig. 1B). 
Consistent with RNA-seq results, GPx7 expression was sig-
nificantly increased only in NASH fibrosis, but not in simple 
steatosis (Fig. 1C). These results suggest that increased GPx7 
expression in NASH fibrosis may mediate the pathological 
mechanism of NASH fibrosis.
GPx7 plays a critical role in NASH fibrosis progression 
regulating oxidative stress
Next, to evaluate whether GPx7 affects NASH fibrosis, GPx7 
was knocked down in LX-2 cells using siRNA. LX-2 cells 
represent hepatic stellate cell models, which are commonly 
used for the NASH fibrosis model in vitro. As shown in Fig. 2A 
and B, fibrosis- and inflammation-related genes were sig-
nificantly upregulated in GPx7-siRNA-transfected LX-2 cells. In 
Sirius Red staining, the knockdown of GPx7 induced collagen 
deposition (Fig. 2C). These results suggest that inhibition of 
GPx7 aggravates the progression of NASH fibrosis. Consist-
ently, GPx7 overexpression in LX-2 cells decreased pro-fibrotic 
and pro-inflammatory gene expression (Fig. 2D). Since GPx7 
has been reported as an antioxidant against oxidative stress 
(21), we measured the cellular ROS production in GPx7- 
overexpressed LX-2 cells to confirm the status of oxidative 
stress. As expected, the overexpression of GPx7 in LX-2 cells 
reduced fluorescence intensity of DCF-DA, indicating decreased 
ROS production (Fig. 2E). These results indicate that GPx7 
inhibits NASH fibrosis progression by suppressing cellular 
levels of oxidative stress. 
Knockdown of GPx7 accelerates the progression of liver 
fibrosis in CDAHFD-fed mice
To investigate whether the GPx7 deficiency promotes NASH 
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Fig. 3. Knockdown of GPx7 induces NASH fibrosis. (A) Schematic 
diagram of in vivo experiments. (Chow diet, n = 8; CDAHFD group 
and sh-GPx7 group, n = 10). (B) Body weight changes in mice. 
(C) H&E and MTC staining of liver sections derived from mice. 
Collagen, blue; muscle fiber, red. (D) Representative liver tissue 
image. (E) Liver weight and the ratio of liver to body weight in 
mice. (F) Serum ALT and AST level in mice. (G) Serum TG and 
liver TG level in mice. Black-filled circle, CD + Ad-shControl; 
Blue-filled square, CDAHFD + Ad-shControl; Red-filled triangle, 
CDAHFD + Ad-shGPx7. All data are presented ± S.D. *P ＜ 0.05, 
**P ＜ 0.01, ***P ＜ 0.001.
Fig. 4. Knockdown of GPx7 increases hepatic inflammation and 
fibrosis-related gene expression. (A) Relative mRNA expression of 
GPx7. (B, C) Relative mRNA levels of indicated genes. (D) Western 
blotting analysis using indicated antibodies. GAPDH was used as 
the loading control. Black-filled circle, CD + Ad-shControl; Blue- 
filled square, CDAHFD + Ad-shControl; Red-filled triangle, CDAHFD + 
Ad-shGPx7. All data are presented ± S.D. *P ＜ 0.05, **P ＜
0.01, ***P ＜ 0.001.
fibrosis in vivo, we developed hepatic GPx7-deficient mice 
using an adenovirus containing short-hairpin RNA of GPx7 
(Ad-shGPx7). After three weeks of feeding with CDAHFD, the 
C57BL/6 mice were injected Ad-shGPx7 and control virus via 
tail-vein, and the mice were sacrificed seven days later (Fig. 
3A). Ad-shGPx7 had no effect on body weight in the CDAHFD 
group (Fig. 3B). However, hematoxylin & eosin (H&E) staining 
and Masson’s trichrome (MTC) staining showed that CDAHFD 
increased collagen deposition and NASH fibrosis was 
aggravated by GPx7 knockdown in liver (Fig. 3C). Further-
more, disproportionate to the body weight, the liver size was 
increased in Ad-shGPx7-injected mice (Fig. 3D), as evidenced 
by the increased ratio of liver weight and liver to body weight 
(Fig. 3E). In addition, the knockdown of GPx7 led to increased 
serum aspartate transaminase (AST) and alanine transaminase 
(ALT) levels, which are indicators of liver inflammation (Fig. 
3F), suggesting that GPx7 is required for protection against 
hepatic fibrosis and inflammation. However, GPx7 knockdown 
did not affect TG accumulation in serum or liver (Fig 3G). 
To verify the GPx7 reduction and NASH fibrosis-related 
gene expression, RT-PCR was performed using liver samples. 
The GPx7 expression was significantly induced by CDAHFD 
feeding and reduced after Ad-shGPx7 injection (Fig. 4A). 
Consistent with GPx7 reduction, pro-fibrotic and pro-inflam-
matory gene expression was dramatically increased in 
CDAHFD-fed mice liver (Fig. 4B and C). These changes were 
confirmed at the protein level (Fig. 4D). Thus, the knockdown 
of GPx7 accelerated CDAHFD-induced NASH fibrosis.
DISCUSSION
NASH fibrosis is the result of chronic liver injury induced by 
persistent fat accumulation of several cytokines via the 
interaction between HSCs and Kupffer cells, and promotion of 
ECM synthesis by activated HSCs (22). NASH fibrosis is 
characterized by excessive collagen accumulation, lobular and 
portal inflammation, hepatic ballooning and fibrosis (23). 
Moreover, NASH fibrosis acts as an indicator of progressive 
molecular pathogenesis and inflammatory reaction (24). Liver 
cell damage triggered by various causes induces hepatocellular 
carcinoma (HCC) and hepatocyte dysfunction (25). Thus, the 
survival rates of chronic liver disease strongly rely on the 
diagnosis and treatment of NASH fibrosis, which leads to 
irreversible cirrhosis. Nevertheless, a therapeutic strategy against 
NASH fibrosis has yet to be established. Therefore, it is 
important to identify new regulators to develop effective strat-
egies for preventing NASH fibrosis progression. Here, we 
found that GPx7 may play an important role during NASH 
fibrosis via regulation of liver fibrosis-related gene expression 
and oxidative stress. 
HSC activation via induction of TGF- causes NASH fibrosis 
by accumulating ECM (26-28). High-fat diet (HFD) is usually 
used in mouse models of liver injury-mediated HSC activation 
(29, 30). In this study, CDAHFD used to induce NASH fibrosis 
is composed of 60 kcal% fat and 0.1% methionine, without 
containing choline (30). Although fat accumulation accompanied 
by inflammation and fibrosis is a key characteristic of NASH, 
our results showed no changes in serum TG levels due to 
CDAHFD inhibition of VLDL secretion from liver to serum. 
However, CDAHFD induced liver TG accumulation in mice 
and the accumulated TG level was not altered by knockdown 
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of GPx7, suggesting that GPx7 was not involved in fat 
accumulation during NASH progression. Thus, GPx7 may 
regulate NASH progression via fibrosis rather than simple 
steatosis.
Oxidative stress has been reported to play a predominant 
pro-fibrotic role in liver fibrosis (13, 31). GPx7 is a known 
regulator of ROS-dependent oxidative DNA damage in several 
cancer types, such as gastric and esophageal cancers (17). 
However, the exact role of GPx7 in liver disease is not shown. 
In this study, the antioxidant action of GPx7 in liver was 
confirmed by the NASH fibrosis model. To our knowledge, 
this is the first report demonstrating the function of GPx7 in 
NASH fibrosis. HSC activation triggered GPx7 overexpression 
and GPx7 modulated pro-fibrotic gene expression via regu-
lation of intracellular ROS levels. This result indicated that 
oxidative stress contributes to liver fibrosis during NASH 
progression, suggesting that antioxidants may represent thera-
peutic alternatives in NASH fibrosis.
Overall, our findings demonstrate that GPx7 effectively 
ameliorates liver fibrogenesis via inhibition of the oxidative 
stress. GPx7 exhibited a potent anti-fibrotic effect by reducing 
inflammatory cytokine production, improving pathological 
changes, and inhibiting ROS production. Taken together, GPx7 




Male C57BL/J mice were purchased from Japan SLC, Inc 
(Shinzuoka, Japan). The animals were maintained in a temper-
ature-controlled room (22oC) on a 12:12-h light-dark cycle. 
Six-week-old mice were fed a normal chow-diet for normal 
control model, and CDAHFD (Choline-deficient, L-amino acid- 
defined, high-fat diet, Research Diets, New Brunswick, NJ, 
USA) for 3 weeks to develop the NASH fibrosis model. Nine- 
week-old male C57BL/6 mice were injected with adenovirus- 
containing short-hairpin RNA (shRNA) or control recombinant 
adenovirus. Recombinant adenoviruses (1 × 109 pfu) were 
delivered by tail-vein-injection. After seven days, mice are 
sacrificed, securing the liver. All procedures were approved by 
the Committee on Animal Investigations of Yonsei University.
Cell culture
LX-2 cells (human stellate cell line) were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, 
Carlsbad, CA, USA) containing 100 U/mL penicillin, 100 
l/mL streptomycin, supplemented with heat-inactivated 10% 
fetal bovine serum (FBS; Invitrogen) at 37oC, in an atmosphere 
of 95% air and 5% CO2. 
Sirius Red Staining
Sirius Red Staining was used to observe fibrosis in cells. Cells 
were washed in distilled water, and fixed in 70% cold ethanol 
for 15 min. The staining solution was applied to completely 
cover the tissue section and incubated for 60 min. The staining 
solution was removed and cells were rinsed twice with acetic 
acid solution and absolute alcohol. 
FACS analysis
LX-2 cells were transfected with control or GPx7-overexpres-
sing vector. After 24 h, cells were treated with ROS stimulator 
and 5 ng/l TGF-, and after 30 min supplemented with 10 
M H2DCFDA for 15 min. The cells were trypsinized and 
collected by centrifugation, washed with 1× PBS twice. 
Labeled cells were analyzed using a FACS caliber flow 
cytometry system, and data were analyzed using the ModFit 
software (BD Biosciences).
Preparation of recombinant adenovirus
Murine GPx7 was obtained by reverse transcriptase-polymer-
ase chain reaction (RT-PCR) with total RNA obtained from 
C57BL/6 mice. Recombinant adenovirus, containing the 
murine GPx7 gene under the control of the CMV promoter, 
was prepared. An E1 shuttle vector expressing murine GPx7 
was first constructed and then linearized with PmeI digestion. 
The linearized shuttle vector was then cotransformed into 
Escherichia coli BJ5183 along with pAdEasy1 vector. The virus 
was propagated in 293A cells and purified by CsCl density 
purification, dissolved in 1× PBS and stored at −80oC. Viral 
particle numbers were calculated from the measurements of 
absorbance at 260 nm (A260). The multiplicity of infection 
(MOI) was calculated from viral particle number. A recombinant 
adenovirus containing the GFP gene was used as a control.
Measurement of triglyceride level in the hepatocytes
Lipid extracts were prepared by homogenizing 0.2 g of liver in 
chloroform/methanol (2:1, v/v) with a final volume of 4 mL. 
The homogenate was incubated with vortexing for 10 min, 
followed by the addition of 0.8 mL of 50 mM NaCl. The 
mixture was vortexed for 10 min, and then centrifuged at 4oC 
for 10 min. The organic phase (25 l of lower layer) was 
transferred and 25 l of Triton X-100/chloroform (7.5:17.5, 
v/v) was added to samples and vortexed for 10 min. The 
solvents were vaporized with a vacuum evaporator. TG 
concentrations were determined using 25 l of extract in a 
commercial colorimetric assay (Thermo scientific, Waltham, 
MA, USA). Samples and standards were vortexed and 
incubated at 37oC for 30 min. The TG level were calculated 
from measurements of absorbance at 500 nm and expressed as 
mg TG/g liver wet weight.
Histological analysis
The liver tissues were fixed in 10% neutral-buffered formalin. 
Following fixation, the liver was trimmed, cryoembedded, 
sectioned, and stained with hematoxylin and eosin (H&E) (32) 
and masson’s trichrome.
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Gene expression analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. 
For RT-PCR, cDNA was synthesized from 5 g of total RNA 
using random hexamer primers and Superscript reverse 
transcriptase III (Invitrogen). Real-time PCR was conducted 
using SYBR Green Master mix (Applied Biosystems, Foster 
city, CA, USA) in a total volume of 20 l. Transcripts were 
detected by real-time qPCR with a Step One instrument 
(Applied Biosystems). All data were normalized to 18S and 
quantitative measures, and were obtained using the -Ct 
method. All reactions were perfomed in duplicate. The relative 
expression levels and S.D. values were calculated using the 
comparative method.
Transient transfection assay 
Cells were plated on 60-mm diameter dishes 24 h before 
transfection. The following double-stranded stealth siRNA 
oligonucleotides (Snata Cruz Biotechnologh) were used: mouse 
GPx7 siRNA oligonucleotides (sc-78832). Control oligonucle-
otides with comparable GC content were also obtained from 
Invitrogen. For knockdown, cells were transfected with control 
or gene-specific siRNA at 60 nM in OPTI-MEM medium using 
Lipofectamine RNAiMAX (Invitrogen), according to the manu-
facturer’s protocol. The next day, the medium was replaced 
with fresh DMEM containing 10% FBS, 100 U/mL penicillin 
and 100 g/mL streptomycin, and the cells were incubated for 
24 h before harvest. Total RNA extracts were prepared from 
the cell at the indicated time point (2 days), and RT-PCR or 
real-time PCR was performed. For the overexpression, the cells 
were plated at a density of 5 × 105 cells/well. The plasmid, 
GPx7 overexpressing vector (pcDNA3-GPx7-FLAG) was packaged 
with Lipofectamine 2000 (Invitrogen), and cells were trans-
fected with either a control or GPx7-overexpressing vector 
according to the manufacturer’s instructions.
Western blot analysis and antibodies
For protein analysis, cells were washed with 1× PBS and lysed 
in a buffer containing 1% sodium dodecyl sulfate (SDS) and 60 
mM Tris-Cl, pH 6.8, and tissues were lysed in PRO-PREPTM 
(iNtRON Biotechnology). The lysate was mixed briefly using a 
vortex, boiled for 10 min, and centrifuged at 13,000 g for 10 
min at 4oC. Protein concentrations were assessed using the 
BCA assay kit (Pierce). Protein samples of equal amount were 
separated by SDS-PAGE and transferred to nitrocellulose mem-
branes. Immunoblot analysis were performed using the following 
antibodies: polyclonal antibodies against GPx7 (Proteintech), 
Col11 (Abcam), TNF (Cell Signaling), SMA, TIMP1, 
MMP13, ADRP, and GAPDH (Santa Cruz Biotechnology).
Statistical analysis
All results are expressed as mean ± S.D. Statistical com-
parisons of groups were made using an unpaired Student’s test. 
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